Double-Blind, Randomized Clinical Trial on the Effect of Interferon-Beta in the Treatment of Condylomata Acuminata

Olmos, L.; Vilata, J.J.; Pichardo, A. Rodríguez; Lloret, Ana; Ojeda, Alejandro González; Calderon, Mariara

doi:10.1177/095646249400500305

Cited by 13 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, we included 12 studies, which involved a total of 1445 patients. Among them, 11 were published in English [18-28], 1 in Chinese(available only by searching the database of CNKI). Apart from Chinese and English, we did not search citations in other languages.…”

Section: Resultsmentioning

confidence: 99%

“…This could be confirmed by the 20-30% rate of spontaneous remission during the first year of infection among otherwise healthy patients, and, on the other hand by the extensive refractory disease observed among immunosuppressed patients [28,29]. Conventional treatments for genital warts, including physical or chemical ablation of warts, may cause local issues such as inflammation, pain, ulceration or scars [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interferon for the treatment of genital warts: a systematic review

Yang

Zeng

et al. 2009

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundInterferon has been widely used in the treatment of genital warts for its immunomodulatory, antiproliferative and antiviral properties. Currently, no evidence that interferon improves the complete response rate or reduces the recurrence rate of genital warts has been generally provided. The aim of this review is to assess, from randomized control trials (RCTs), the efficacy and safety of interferon in curing genital warts.MethodsWe searched Cochrane Sexually Transmitted Diseases Group's Trials Register (January, 2009), Cochrane Central Register of Controlled Trials (2009, issue 1), PubMed (1950-2009), EMBASE (1974-2009), Chinese Biomedical Literature Database (CBM) (1975-2009), China National Knowledge Infrastructure (CNKI) (1979-2009), VIP database (1989-2009), as well as reference lists of relevant studies. Two reviewers independently screened searched studies, extracted data and evaluated their methodological qualities. RevMan 4.2.8 software was used for meta-analysisResults12 RCTs involving 1445 people were included. Among them, 7 studies demonstrated the complete response rate of locally-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions differed significantly (locally-used interferon:44.4%; placebo:16.1%). The difference between the two groups had statistical significance (RR 2.68, 95% CI 1.79 to 4.02, P < 0.00001). 5 studies demonstrated the complete response rate of systemically-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions had no perceivable discrepancy (systemically-used interferon:27.4%; placebo:26.4%). The difference between the two groups had no statistical significance (RR1.25, 95% CI 0.80 to 1.95, P > 0.05). 7 studies demonstrated the recurrence rate of interferon as compared to placebo for treating genital warts. Based on meta-analysis, the recurrence rate of the two interventions had no perceivable discrepancy(interferon 21.1%; placebo: 34.2%). The difference between the two groups had no statistical significance (RR0.56, 95% CI 0.27 to 1.18, P > 0.05). However, subgroup analysis showed that HPV-infected patients with locally administered interferon were less likely than those given placebo to relapse, but that no significant difference in relapse rates was observed between systemic and placebo. The reported adverse events of interferon were mostly mild and transient, which could be well tolerated.ConclusionInterferon tends to be a fairly well-tolerated form of therapy. According to different routes of administration, locally-used interferon appears to be much more effective than both systemically-used interferon and placebo in either improving the complete response rate or reducing the recurrence rate for the treatment of genital warts.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interferon for the treatment of genital warts: a systematic review

Yang

Zeng

et al. 2009

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…At day 22, (table) a total of 72 lesions had been treated and observed. Of these, 15/24 (63%) of lesions injected with 1 x 106 IU r-hIFN-beta showed a CR, compared with 9/24 (38%) and 5/24 (21%) injected with 33,000 IU r-hIFN-beta and placebo respectively. The number of CRs resulting from the higher dose was significantly higher than that resulting from treatment with placebo (p = 0.0063, McNemar test, two-sided), while not significantly different from the lower dose (p = 0 34, McNemar test).…”

Section: Resultsmentioning

confidence: 96%

“…We thank Dr I Trinchard-Lugan for monitoring the study, and Dr PE Engrand for assisting in the interpretation of data.This trial was sponsored by a grant from Ares-Serono SA, 15 bis, chemin des Mines, 1202 Geneva, Switzerland.…”

mentioning

confidence: 99%

Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum.

Monsonégo

Cessot

İnce

et al. 1996

Sexually Transmitted Infections

View full text Add to dashboard Cite

Objective: To evaluate the safety and efficacy of two intralesional doses of recombinant human interferon-beta (r-hIFN-beta: Rebif X, Ares Serono), given 3 times a week for 3 weeks, in the treatment of condyloma acuminatum. Design: A randomised, double-blind, within-patient, placebo-controlled study. Subjects: 25 patients (24 males, 1 female) with a history of condyloma acuminatum. Twenty had failed previous treatment for condyloma acuminatum. In each patient, 3 distinct lesions were selected for treatmnent. Each selected lesion was randomly assigned to receive intralesionally one of the following: r-hIFN-beta 33,000 lU/day, r-hIFN-beta 1 x 106 IU/day, or matching placebo. Setting: Institut Alfred Fournier, Paris, France. Outcome measures: Response was evaluated colposcopically at the end of treatment (day 22) and 5 weeks later (month 2). Complete response (CR) was defined as disappearance of the treated lesion. Partial response (PR) was defined as at least a 50% reduction in size, but not disappearance of the treated lesion. Results: The higher dose of 1 x 106 IU achieved significantly more complete and partial remissions than placebo, both by the end of treatment, and 5 weeks later. Conclusions: r-hIFN-beta appears to be safe and effective when administered intralesionally to patients with condyloma acuminatum. Most of the treated patients had failed previous treatments and were therefore a resistant population.

show abstract

“…Placebo controlled randomized trials have generally found intralesional therapy to be most effective, 52 while evidence for the efficacy of systemic and topical therapy has been inconsistent. [53][54][55][56] Intralesional injection of 0.5 to 1.5 million international units per lesion is administered two to three times per week for up to three weeks. The course of therapy can be repeated 12 to 16 weeks from the initial treatment.…”

Section: Interferonsmentioning

confidence: 99%

Anogenital siğiller: İnsan papilloma virüsü, klinik bulguları ve tedavi stratejileri üzerine bir güncelleme

Kılıç¹,

Ural

2019

Mucosa

View full text Add to dashboard Cite

Anogenital warts is a major health problem caused by human papilloma virus (HPV). To date, more than 200 subtypes of HPV exist. Depending on the type of HPV and the immune status of the patient, various clinical forms may appear. The most detected types are HPV-6 and 11 which are responsible for approximately 90% of anogenital warts. High oncogenic strains HPV types 16 and 18 are responsible not only for cervical cancer, but also other cancers such as vagina, vulva, penile, anus, head and neck. Besides, anogenital warts impact the individual's quality of life leading significant psychosocial problems. Treatment options for anogenital warts include cytodestructive, immune-mediated and surgical therapies. Treatment choice depends on the location, number, and size of the warts; patient situation (eg. pregnancy, ability to comply with therapy, immunosuppression); availability of clinical expertise; and patient preferences, cost, and convenience. This article updates the epidemiological, etiological, clinical features and therapeutic choices in anogenital warts. Anogenital siğiller: İnsan papilloma virüsü, klinik bulguları ve tedavi stratejileri üzerine bir güncelleme Özet Anogenital siğiller insan papilloma virüsünün (HPV) neden olduğu önemli bir sağlık sorunudur. Bugüne kadar, 200'den fazla HPV alt tipi saptanmıştır. HPV tipine ve hastanın bağışıklık durumuna bağlı olarak, anogenital siğillerde çeşitli klinik formlar gözlenebilir. En çok tespit edilen tipler HPV-6 ve HPV 11 olup anogenital siğillerin yakla-şık% 90'ından sorumludur. Yüksek onkojenik suşlar HPV tip 16 ve 18 sadece servikal kanserden değil, vajina, vulva, penis, anüs, baş ve boyun gibi diğer kanserlerden de sorumludur. Ayrıca, anogenital siğiller, bireyin yaşam kalitesini etkileyerek önemli psikososyal sorunlara neden olur. Anogenital siğiller için tedavi seçenekleri arasında destrüktif, immün modülatör ve cerrahi tedaviler bulunmaktadır. Tedavi seçimi siğillerin yeri, sayısı ve büyüklüğüne; hastanın durumuna (örneğin, hamilelik, tedaviye uyma yeteneği, immün baskılama); klinisyenin tecrübesine; ve hastanın tercihleri ve rahatlığına bağlıdır. Bu makale anogenital siğillerdeki epidemiyolojik, etiyolojik, klinik özellikleri ve tedavi seçeneklerini güncellemektedir. Anahtar kelimeler: anogenital siğiller, insan papilloma virüsü, tedavi

show abstract

Double-Blind, Randomized Clinical Trial on the Effect of Interferon-Beta in the Treatment of Condylomata Acuminata

Cited by 13 publications

References 9 publications

Interferon for the treatment of genital warts: a systematic review

Interferon for the treatment of genital warts: a systematic review

Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum.

Anogenital siğiller: İnsan papilloma virüsü, klinik bulguları ve tedavi stratejileri üzerine bir güncelleme

Contact Info

Product

Resources

About